Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Wenxin Xu, M.D.

Co-Author

This page shows the publications co-authored by Wenxin Xu and David McDermott.
Connection Strength

1.335
  1. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol. 2020 03; 17(3):137-150.
    View in: PubMed
    Score: 0.857
  2. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2020 06; 18(3):179-184.e3.
    View in: PubMed
    Score: 0.212
  3. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. Clin Cancer Res. 2019 10 15; 25(20):6098-6106.
    View in: PubMed
    Score: 0.208
  4. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021 05 10; 39(5):632-648.e8.
    View in: PubMed
    Score: 0.058
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.